1
|
Leung ELH, Li RZ, Fan XX, Wang LY, Wang Y, Jiang Z, Huang J, Pan HD, Fan Y, Xu H, Wang F, Rui H, Wong P, Sumatoh H, Fehlings M, Nardin A, Gavine P, Zhou L, Cao Y, Liu L. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy. Nat Commun 2023; 14:5115. [PMID: 37607911 PMCID: PMC10444872 DOI: 10.1038/s41467-023-40631-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Accepted: 08/02/2023] [Indexed: 08/24/2023] Open
Abstract
Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung cancer (NSCLC) patients undergoing anti-PD1 therapy by high-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokines measurements. We find that higher proportions of circulating CD8+ and of CD8+CD101hiTIM3+ (CCT T) subsets significantly correlate with poor clinical response to immune therapy. Consistently, CD8+ T cells and CCT T cell frequencies remain low in most responders during the entire multi-cycle treatment regimen; and higher killer cell lectin-like receptor subfamily G, member 1 (KLRG1) expression in CCT T cells at baseline associates with prolonged progression free survival. Upon in vitro stimulation, CCT T cells of responders produce significantly higher levels of cytokines, including IL-1β, IL-2, IL-8, IL-22 and MCP-1, than of non-responders. Overall, our results provide insights into the longitudinal immunological landscape underpinning favourable response to immune checkpoint blockade therapy in lung cancer patients.
Collapse
Affiliation(s)
- Elaine Lai-Han Leung
- Cancer Center, Faculty of Health Sciences; MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China.
| | - Run-Ze Li
- State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangdong, China
| | - Xing-Xing Fan
- Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery/State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute of Applied Research in Medicine and Health, Macau University of Science and Technology, Avenida Wai Long, Macao, Taipa Macau (SAR), China
| | | | - Yan Wang
- Merck Sharp & Dohme, Shanghai, China
| | - Zebo Jiang
- Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery/State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute of Applied Research in Medicine and Health, Macau University of Science and Technology, Avenida Wai Long, Macao, Taipa Macau (SAR), China
| | - Jumin Huang
- Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery/State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute of Applied Research in Medicine and Health, Macau University of Science and Technology, Avenida Wai Long, Macao, Taipa Macau (SAR), China
| | - Hu-Dan Pan
- State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangdong, China
| | - Yue Fan
- Janssen Research & Development, Shanghai, China
| | - Hongmei Xu
- Janssen Research & Development, Shanghai, China
| | - Feng Wang
- Janssen Research & Development, Shanghai, China
| | - Haopeng Rui
- Janssen Research & Development, Shanghai, China
| | - Piu Wong
- HiFiBio Therapeutics, Hongkong, China
| | | | | | | | - Paul Gavine
- Janssen Research & Development, Shanghai, China
| | - Longen Zhou
- Janssen Research & Development, Shanghai, China
| | | | - Liang Liu
- State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China.
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, Guangdong, China.
| |
Collapse
|
2
|
Fu L, Zhang J, Shen B, Kong L, Liu Y, Tu W, Wang W, Cai X, Wang X, Cheng N, Xia M, Zhou T, Liu Q, Xu Y, Yang J, Gavine P, Philippar U, Attar R, Edwards JP, Venable JD, Dai X. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL. J Med Chem 2021; 64:10878-10889. [PMID: 34279092 DOI: 10.1021/acs.jmedchem.1c00103] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
MyD88 gene mutation has been identified as one of the most prevalent driver mutations in the activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL). The published literature suggests that interleukin-1 receptor-associated kinase 1 (IRAK1) is an essential gene for ABC DLBCL harboring MyD88 mutation. Importantly, the scaffolding function of IRAK1, rather than its kinase activity, is required for tumor cell survival. Herein, we present our design, synthesis, and biological evaluation of a novel series of potent and selective IRAK1 degraders. One of the most potent compounds, Degrader-3 (JNJ-1013), effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells. Furthermore, JNJ-1013 potently inhibited IRAK1 downstream signaling pathways and demonstrated strong anti-proliferative effects in ABC DLBCL cells with MyD88 mutation. This work suggests that IRAK1 degraders have the potential for treating cancers that are dependent on the IRAK1 scaffolding function.
Collapse
Affiliation(s)
- Liqiang Fu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Jing Zhang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Bin Shen
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Linglong Kong
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Yingtao Liu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Wangyang Tu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Wenqian Wang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Xin Cai
- Department of Biomarker, Janssen Research & Development, Shanghai 201210, China
| | - Xiaotao Wang
- Department of Biomarker, Janssen Research & Development, Shanghai 201210, China
| | - Na Cheng
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Mingxuan Xia
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Tianyuan Zhou
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Qian Liu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Yanping Xu
- Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| | - Jennifer Yang
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Paul Gavine
- Department of Biology, Janssen Research & Development, Shanghai 201210, China
| | - Ulrike Philippar
- Janssen Pharmaceutical Research & Development, Beerse 2340, Belgium
| | - Ricardo Attar
- Janssen Pharmaceutical Research & Development, Spring House, Pennsylvania 19477, United States
| | - James P Edwards
- Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States
| | - Jennifer D Venable
- Discovery Sciences, Janssen Research & Development, San Diego, California 92121, United States
| | - Xuedong Dai
- Discovery Sciences, Janssen (China) Research & Development, Shanghai 201210, P.R. China.,Discovery Chemistry, Janssen Research & Development, Shanghai 201210, China
| |
Collapse
|
3
|
Zhang J, Fu L, Shen B, Liu Y, Wang W, Cai X, Kong L, Yan Y, Meng R, Zhang Z, Chen YNP, Liu Q, Wan ZK, Zhou T, Wang X, Gavine P, Del Rosario A, Ahn K, Philippar U, Attar R, Yang J, Xu Y, Edwards JP, Dai X. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. Cell Chem Biol 2020; 27:1500-1509.e13. [PMID: 32888499 DOI: 10.1016/j.chembiol.2020.08.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 07/29/2020] [Accepted: 08/17/2020] [Indexed: 12/13/2022]
Abstract
The interleukin-1 receptor-activated kinase 4 (IRAK4) belongs to the IRAK family of serine/threonine kinases and plays a central role in the innate immune response. However, the function of IRAK4 in tumor growth and progression remains elusive. Here we sought to determine the enzymatic and scaffolding functions of IRAK4 in activated B-cell-like diffuse large B cell lymphoma (ABC DLBCL). We chose a highly selective IRAK4 kinase inhibitor to probe the biological effects of kinase inhibition and developed a series of IRAK4 degraders to evaluate the effects of protein degradation in ABC DLBCL cells. Interestingly, the results demonstrated that neither IRAK4 kinase inhibition nor protein degradation led to cell death or growth inhibition, suggesting a redundant role for IRAK4 in ABC DLBCL cell survival. IRAK4 degraders characterized in this study provide useful tools for understanding IRAK4 protein scaffolding function, which was previously unachievable using pharmacological perturbation.
Collapse
Affiliation(s)
- Jing Zhang
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Liqiang Fu
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Bin Shen
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Yingtao Liu
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Wenqian Wang
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Xin Cai
- Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Linglong Kong
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Yilin Yan
- Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Ryan Meng
- Nonclinical Safety, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Zhuming Zhang
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Ying-Nan P Chen
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Qian Liu
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Zhao-Kui Wan
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Tianyuan Zhou
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Xiaotao Wang
- Biomarker, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Paul Gavine
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Amanda Del Rosario
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Kay Ahn
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Ulrike Philippar
- Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Ricardo Attar
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Jennifer Yang
- Oncology Biology, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - Yanping Xu
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China
| | - James P Edwards
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Xuedong Dai
- Medicinal Chemistry, Janssen (China) Research & Development Center, Shanghai 201210, China.
| |
Collapse
|
4
|
Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, Gavine P, Cui A, Ling S, Stott J, Clark R, Peel S, Gill P, Goodwin LM, Smith A, Pike KG, Barlaam B, Pass M, O'Connor MJ, Smith G, Cadogan EB. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. Mol Cancer Ther 2019; 19:13-25. [PMID: 31534013 DOI: 10.1158/1535-7163.mct-18-1394] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 06/13/2019] [Accepted: 09/11/2019] [Indexed: 11/16/2022]
Abstract
AZD0156 is a potent and selective, bioavailable inhibitor of ataxia-telangiectasia mutated (ATM) protein, a signaling kinase involved in the DNA damage response. We present preclinical data demonstrating abrogation of irradiation-induced ATM signaling by low doses of AZD0156, as measured by phosphorylation of ATM substrates. AZD0156 is a strong radiosensitizer in vitro, and using a lung xenograft model, we show that systemic delivery of AZD0156 enhances the tumor growth inhibitory effects of radiation treatment in vivo Because ATM deficiency contributes to PARP inhibitor sensitivity, preclinically, we evaluated the effect of combining AZD0156 with the PARP inhibitor olaparib. Using ATM isogenic FaDu cells, we demonstrate that AZD0156 impedes the repair of olaparib-induced DNA damage, resulting in elevated DNA double-strand break signaling, cell-cycle arrest, and apoptosis. Preclinically, AZD0156 potentiated the effects of olaparib across a panel of lung, gastric, and breast cancer cell lines in vitro, and improved the efficacy of olaparib in two patient-derived triple-negative breast cancer xenograft models. AZD0156 is currently being evaluated in phase I studies (NCT02588105).
Collapse
Affiliation(s)
- Lucy C Riches
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | | | - Gareth Hughes
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Gemma N Jones
- Translational Medicine, Oncology R&D, Oncology, AstraZeneca, Cambridge, United Kingdom
| | - Adina M Hughes
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | | | - Paul Gavine
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Andy Cui
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Stephanie Ling
- Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
| | - Jonathan Stott
- Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
| | - Roger Clark
- Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
| | - Samantha Peel
- Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
| | - Pendeep Gill
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Louise M Goodwin
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Aaron Smith
- DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Kurt G Pike
- Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Bernard Barlaam
- Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Martin Pass
- Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Mark J O'Connor
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Graeme Smith
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
| | - Elaine B Cadogan
- Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
| |
Collapse
|
5
|
Chen H, Ye Q, Lv J, Ye P, Sun Y, Fan S, Su X, Gavine P, Yin X. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. Pathol Oncol Res 2015; 21:947-55. [PMID: 25749810 PMCID: PMC4550655 DOI: 10.1007/s12253-015-9909-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Accepted: 02/16/2015] [Indexed: 12/27/2022]
Abstract
The aim of the study was to investigate trastuzumab anti-tumor efficacy and its correlation with HER-2 status in primary xenograft models derived from Chinese patients with gastric adenocarcinoma. Patient-derived gastric adenocarcinoma xenograft (PDGAX) mouse models were firstly generated by implanting gastric adenocarcinoma tissues from patients into immune deficient mice. A high degree of histological and molecular similarity between the PDGAX mouse models and their corresponding patients’ gastric adenocarcinoma tissues was shown by pathological observation, HER-2 expression, HER-2 gene copy number, and mutation detection. Based on Hoffmann’s criteria in gastric cancer, three models (PDGAX001, PDGAX003 and PDGAX005) were defined as HER-2 positive with fluorescence in situ hybridization (FISH) amplification or immunohistochemistry (IHC) 2+/ 3+, while two models (PDGAX002, PDGAX004) were defined as HER-2 negative. Upon trastuzumab treatment, significant tumor regression (105 % TGI) was observed in model PDGAX005 (TP53 wt), while moderate sensitivity (26 % TGI) was observed in PDGAX003, and resistance was observed in PDGAX001, 002 and 004. A significant increase in HER-2 gene copy number was only observed in PDGAX005 (TP53 wt). Interestingly, trastuzumab showed no efficacy in PDGAX001 (HER2 IHC 3+ and FISH amplification, but with mutant TP53). Consistent with this finding, phosphor-HER2 modulation by trastuzumab was observed in model PDGAX005, but not in PDGAX001.
Collapse
Affiliation(s)
- Hao Chen
- Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160 Pujian Road, Shanghai, 200127 China
| | - Qingqing Ye
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Jing Lv
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Peng Ye
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Yun Sun
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Shuqiong Fan
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Xinying Su
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Paul Gavine
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| | - Xiaolu Yin
- Department of Translational Science, Asia & Emerging Market iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai, 201203 China
| |
Collapse
|
6
|
Zhang T, Lu Y, Ye Q, Zhang M, Zheng L, Yin X, Gavine P, Sun Z, Ji Q, Zhu G, Su X. An evaluation and recommendation of the optimal methodologies to detectRETgene rearrangements in papillary thyroid carcinoma. Genes Chromosomes Cancer 2014; 54:168-76. [DOI: 10.1002/gcc.22229] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Revised: 10/22/2014] [Accepted: 11/03/2014] [Indexed: 01/21/2023] Open
Affiliation(s)
- Tianwei Zhang
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Yachao Lu
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Qingqing Ye
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Meizhuo Zhang
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Li Zheng
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Xiaolu Yin
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Paul Gavine
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Zhongsheng Sun
- Institute of Genomic Medicine; Wenzhou Medical University; Wenzhou Zhejiang 325000 China
| | - Qunsheng Ji
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Guanshan Zhu
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| | - Xinying Su
- Asia & Emerging Markets iMed; AstraZeneca R&D. 199 LiangJing Road, ZhangJiang Hi-Tech Park Shanghai 201203 China
| |
Collapse
|
7
|
D'Cruz C, Frigault M, Adam A, Shen M, Beran G, Barry E, Gavine P, Ren Y, Fan S, Zhou F, Qing W, Zinda M, Su W, Clark E. Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC. Tumour Biol 2014. [DOI: 10.1158/1538-7445.am2014-3114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
8
|
Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer 2014; 110:1169-78. [PMID: 24518603 PMCID: PMC3950883 DOI: 10.1038/bjc.2014.61] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2013] [Revised: 12/24/2013] [Accepted: 01/08/2014] [Indexed: 02/06/2023] Open
Abstract
Background: Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval
of trastuzumab, targeted therapies are emerging as promising treatment options for the
disease. This study aimed to explore the molecular segmentation of several known
therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and
fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or
investigational kits and scoring criteria. Knowledge of how these markers are segmented
in the same cohort of GC patients could improve future clinical trial designs. Methods: Using immunohistochemistry (IHC) and FISH methods, overexpression and amplification of
HER2, FGFR2 and MET were profiled in a cohort of Chinese GC samples. The correlations
between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2
alterations were further tested in a panel of GC cell lines and the patient-derived GC
xenograft (PDGCX) model using the targeted inhibitors. Results: Of 172 GC patients, positivity for HER2, MET and FGFR2 alternations was found in 23
(13.4%), 21 (12.2%) and 9 (5.2%) patients, respectively. Positivity
for MET was found in 3 of 23 HER2-positive GC patients. Co-positivity for FGFR2 and MET
was found in 1 GC patient, and amplification of the two genes was found in different
tumour cells. Our study in a panel of GC cell lines showed that in most cell lines,
amplification or high expression of a particular molecular marker was mutually exclusive
and in vitro sensitivity to the targeted agents lapatinib, PD173074 and
crizotinib was only observed in cell lines with the corresponding high expression of the
drugs' target protein. SGC031, an MET-positive PDGCX mouse model, responded to
crizotinib but not to lapatinib or PD173074. Conclusions: Human epidermal growth factor receptor 2, MET and FGFR2 oncogenic driver alterations
(gene amplification and overexpression) occur in three largely distinct molecular
segments in GC. A significant proportion of HER2-negative patients may potentially
benefit from MET- or FGFR2-targeted therapies.
Collapse
Affiliation(s)
- Y J Liu
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - D Shen
- Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai 200127, China
| | - X Yin
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - P Gavine
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - T Zhang
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - X Su
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - P Zhan
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - Y Xu
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - J Lv
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - J Qian
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - C Liu
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - Y Sun
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - Z Qian
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - J Zhang
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - Y Gu
- Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China
| | - X Ni
- Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai 200127, China
| |
Collapse
|
9
|
Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, Wu YL. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med 2013; 11:168. [PMID: 23842453 PMCID: PMC3716998 DOI: 10.1186/1479-5876-11-168] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Accepted: 07/08/2013] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Patient-derived tumor xenograft models have been established and increasingly used for preclinical studies of targeted therapies in recent years. However, patient-derived non-small cell lung cancer (NSCLC) xenograft mouse models are relatively few in number and are limited in their degree of genetic characterization and validation. In this study, we aimed to establish a variety of patient-derived NSCLC models and characterize these for common genetic aberrations to provide more informative models for preclinical drug efficacy testing. METHODS NSCLC tissues from thirty-one patients were collected and implanted into immunodeficient mice. Established xenograft models were characterized for common genetic aberrations, including detection of gene mutations within EGFR and KRAS, and genetic amplification of FGFR1 and cMET. Finally, gefitinib anti-tumor efficacy was tested in these patient-derived NSCLC xenograft models. RESULTS Ten passable patient-derived NSCLC xenograft models were established by implantation of NSCLC specimens of thirty-one patients into immunodeficient mice. Genetic aberrations were detected in six of the models, including one model with an EGFR activating mutation (Exon19 Del), one model with KRAS mutation, one model with both KRAS mutation and cMET gene amplification, and three models with FGFR1 amplification. Anti-tumor efficacy studies using gefitinib demonstrated that the EGFR activating mutation model had superior sensitivity and that the KRAS mutation models were resistant to gefitinib. The range of gefitinib responses in the patient-derived NSCLC xenograft models were consistent with the results reported from clinical trials. Furthermore, we observed that patient-derived NSCLC models with FGFR1 gene amplification were insensitive to gefitinib treatment. CONCLUSIONS Ten patient-derived NSCLC xenograft models were established containing a variety of genetic aberrations including EGFR activating mutation, KRAS mutation, and FGFR1 and cMET amplification. Gefitinib anti-tumor efficacy in these patient-derived NSCLC xenografts containing EGFR and KRAS mutation was consistent with the reported results from previous clinical trials. Thus, data from our panel of patient-derived NSCLC xenograft models confirms the utility of these models in furthering our understanding of this disease and aiding the development of personalized therapies for NSCLC patients.
Collapse
Affiliation(s)
- Xu-chao Zhang
- Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute Guangzhou 510080, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kilgour E, Su X, Zhan P, Gavine P, Morgan S, Womack C, Jung EJ, Bang YJ, Im SA, Kim WH, Grabsch H. Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.4124] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4124 Background: Gastric adenocarcinoma is the 4th most common cancer, and many patients present with metastatic or recurrent disease. The prognosis for these patients is poor, with median survival times of 11–12 months. Hence there is a need for identification of potential new drug targets. We have determined the prevalence of FGFR2 gene amplification (FGFR2amp) and its relationship to clinicopathological parameters and survival in Caucasian (n=408) and Korean (n=356) gastric cancers (GC) and determined the overlap with HER2 or cMET gene amplification. Methods: FGFR2, HER2 and cMET gene amplification was assessed by fluorescence in situ hybridisation in GC tissue microarrays from Caucasian and Korean surgically resected gastric carcinomas. Gene amplification was defined as a gene/centromeric probe ratio of ≥2.0 after measuring at least 50 tumour cells. Results: 7% (30/408) of Caucasian and 4% (15/356) of Korean GC showed FGFR2amp, and the incidence was not significantly different between these cohorts (p=0.092). FGFR2amp was significantly associated with lymph node status in both cohorts (p<0.0007, multivariate analysis), and in the Korean cohort with diffuse-type histology, but not with depth of tumour invasion, age or gender. Patients with FGFR2amp showed significantly shorter overall survival in both the Caucasian (HR 2.37, 95% CI 1.6–3.5; p=0.0001) and Korean (HR 2.33, 95% CI 1.28–4.25; p=0.0129) cohorts, by multivariate analysis. There was no overlap between FGFR2amp and HER2 or cMET amplification in the Korean cohort, but two of twenty-six FGFR2amp Caucasian gastric tumours also showed HER2 amplification. Conclusions: This is the first study to demonstrate FGFR2amp, at a prevalence of 4% and 7%, in two large GC cohorts of Asian and Caucasian origin and that FGFR2amp is prognostic and significantly associated with lymph node metastasis. Furthermore, FGFR2amp is generally mutually exclusive with HER2 and cMET amplifications. Based on these observations, FGFR2 inhibitors warrant further investigation in the treatment of FGFR2 amplified GCs.
Collapse
Affiliation(s)
- Elaine Kilgour
- AstraZeneca, Oncology Innovative Medicines, Macclesfield, United Kingdom
| | - Xinying Su
- AstraZeneca Innovation Center China, Shanghai, China
| | - Ping Zhan
- AstraZeneca, Innovation Center China, Shanghai, China
| | - Paul Gavine
- AstraZeneca, Innovation Center China, Shanghai, China
| | | | - Chris Womack
- AstraZeneca, Oncology Innovative Medicines, Macclesfield, United Kingdom
| | | | - Yung-Jue Bang
- Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Seock-Ah Im
- Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
| | - Woo Ho Kim
- Department of Pathology, Seoul National University Hospital, Seoul, South Korea
| | - Heike Grabsch
- Leeds Institute of Molecular Medicine, Leeds, United Kingdom
| |
Collapse
|
11
|
Abstract
PURPOSE Extensive correlative studies in human prostate cancer as well as studies in vitro and in mouse models indicate that fibroblast growth factor receptor (FGFR) signaling plays an important role in prostate cancer progression. In this study, we used a probe compound for an FGFR inhibitor, which potently inhibits FGFR-1-3 and significantly inhibits FGFR-4. The purpose of this study is to determine whether targeting FGFR signaling from all four FGFRs will have in vitro activities consistent with inhibition of tumor progression and will inhibit tumor progression in vivo. EXPERIMENTAL DESIGN Effects of AZ8010 on FGFR signaling and invasion were analyzed using immortalized normal prostate epithelial (PNT1a) cells and PNT1a overexpressing FGFR-1 or FGFR-4. The effect of AZ8010 on invasion and proliferation in vitro was also evaluated in prostate cancer cell lines. Finally, the impact of AZ8010 on tumor progression in vivo was evaluated using a VCaP xenograft model. RESULTS AZ8010 completely inhibits FGFR-1 and significantly inhibits FGFR-4 signaling at 100 nmol/L, which is an achievable in vivo concentration. This results in marked inhibition of extracellular signal-regulated kinase (ERK) phosphorylation and invasion in PNT1a cells expressing FGFR-1 and FGFR-4 and all prostate cancer cell lines tested. Treatment in vivo completely inhibited VCaP tumor growth and significantly inhibited angiogenesis and proliferation and increased cell death in treated tumors. This was associated with marked inhibition of ERK phosphorylation in treated tumors. CONCLUSIONS Targeting FGFR signaling is a promising new approach to treating aggressive prostate cancer.
Collapse
Affiliation(s)
- Shu Feng
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | |
Collapse
|